Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPIDER trial of ziltivekimab in coronary artery disease with residual inflammation
NL-OMON59727Phase 3Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronary arteriosclerosis comparing Ziltivekimab with Placebo (2 arms). Primary endpoint: Mean percentage change in coronary arterial inflammation and monocyte activation markers. Started Nov 2024; status: active, not recruiting.
02
Drugs
ziltivekimab
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on NL-OMON59727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59727.